More than 90% of plozasiran-treated patients with severe hypertriglyceridaemia (sHTG) achieved TG levels <500 mg/dL (<5.65 mmol/L) at month 12 in the SHASTA-3 and SHASTA-4 trials, and more than half achieved normalised TG levels <150 mg/dL (<1.69 mmol/L).
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
